Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National surgical adjuvant study for breast cancer 01 trial

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1368-1374

  Watanabe, Toru ^a,b   Sano, Muneaki ^c   Takashima, Shigemitsu ^c   Kitaya, Tomoki ^c   Tokuda, Yutaka ^c   Yoshimoto, Masataka ^c   Kohno, Norio ^c   Nakagami, Kazuhiko ^c   Iwata, Hiroji ^c   Shimozuma, Kojiro ^c   Sonoo, Hiroshi ^c   Tsuda, Hitoshi ^c   Sakamoto, Goi ^c   Ohashi, Yasuo ^c  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Hamamatsu Oncology Center   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; UFT; ANTINEOPLASTIC AGENT; CMF REGIMEN; TEGAFUR; URACIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE FREE SURVIVAL; SIDE EFFECT; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RISK FACTOR;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RISK FACTORS; TEGAFUR; URACIL;

EID: 63049102784     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.3939     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative G: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev CD000487, 2002
2. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007
3. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1988
4. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004
5. Nakajima T, Kinoshita T, Nashimoto A, et al: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 94:1468-1476, 2007
6. Akasu T, Moriya Y, Ohashi Y, et al: Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: A multicenter randomized controlled trial. Jpn J Clin Oncol 36:237-244, 2006
7. Lembersky BC, Wieand HS, Petrelli NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059-2064, 2006
8. Tashiro H, Nomura Y, Ohsaki A: A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol 24:212-217, 1994
9. Kasumi F, Yoshimoto M, Uchino J, et al: Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64:146-153, 2003
10. Noguchi S, Koyama H, Uchino J, et al: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: A pooled analysis of six randomized controlled trials. J Clin Oncol 23:2172-2184, 2005
11. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
12. Findlay M, von Minckwitz G, Wardley A: Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol 19:212-222, 2008
13. Tsuda H, Akiyama F, Kurosumi M, et al: Establishment of histological criteria for high-risk node-negative breast carcinoma for a multiinstitutional randomized clinical trial of adjuvant therapy: Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol 28:486-491, 1998
14. Tsuda H, Akiyama F, Kurosumi M, et al: The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer: The Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol 29:68-73, 1999
15. Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncology Group: The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23:250-257, 1993
16. Groenvold M, Klee MC, Sprangers MAG, et al: Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50:441-450, 1997
17. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997
18. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317:141-145, 1987
19. Watanabe T: Patients' concerns about clinical trials in Japan. The Lancet 353:1019-1020, 1999
20. Korn EL, Hunsberger S, Freidlin B, et al: Preliminary data release for randomized clinical trials of noninferiority: A new proposal. J Clin Oncol 23:5831-5836, 2005
21. Linden HM, Haskell CM, Green SJ, et al: Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: Final analysis from INT-0137 (S9313). J Clin Oncol 25:656-661, 2007
22. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
23. Nikolic-Tomasevic Z, Jelic S, Cassidy J, et al: Fluoropyrimidine therapy: Hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 56:594-602, 2005
24. Duric VM, Stockler MR, Heritier S, et al: Patients' preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794, 2005
25. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
26. Ershler WB: Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. Oncologist 11:325-335, 2006
27. Muss HB, Berry DL, Cirrincione C, et al: Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. J Clin Oncol 26:8s, 2008 (suppl; abstr 507)
28. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
29. Munoz R, Man S, Shaked Y, et al: Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66:3386-3391, 2006